116 related articles for article (PubMed ID: 10973815)
21. [Cyclin D, CDK4 and p16 expression in colorectal cancer].
Ikeda K; Monden T; Tsujie M; Izawa H; Yamamoto H; Ohnishi T; Ohue M; Sekimoto M; Tomita N; Monden M
Nihon Rinsho; 1996 Apr; 54(4):1054-9. PubMed ID: 8920673
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex.
Wang J; Walsh K
Cell Growth Differ; 1996 Nov; 7(11):1471-8. PubMed ID: 8930396
[TBL] [Abstract][Full Text] [Related]
23. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
24. Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells.
Ando K; Griffin JD
Oncogene; 1995 Feb; 10(4):751-5. PubMed ID: 7862452
[TBL] [Abstract][Full Text] [Related]
25. Conditional binding to and cell cycle-regulated inhibition of cyclin-dependent kinase complexes by p27Kip1.
Eblen ST; Fautsch MP; Anders RA; Leof EB
Cell Growth Differ; 1995 Aug; 6(8):915-25. PubMed ID: 8547220
[TBL] [Abstract][Full Text] [Related]
26. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano M; Hannon GJ; Beach D
Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
[TBL] [Abstract][Full Text] [Related]
27. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
29. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.
Mahale S; Aubry C; James Wilson A; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Med Chem Lett; 2006 Aug; 16(16):4272-8. PubMed ID: 16750360
[TBL] [Abstract][Full Text] [Related]
30. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
Sandhu C; Peehl DM; Slingerland J
Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
[TBL] [Abstract][Full Text] [Related]
31. Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts.
Dietrich C; Wallenfang K; Oesch F; Wieser R
Oncogene; 1997 Nov; 15(22):2743-7. PubMed ID: 9401001
[TBL] [Abstract][Full Text] [Related]
32. Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells.
Ehmann GL; McLean TI; Bachenheimer SL
Virology; 2000 Feb; 267(2):335-49. PubMed ID: 10662629
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I.
Iwanaga R; Ohtani K; Hayashi T; Nakamura M
Oncogene; 2001 Apr; 20(17):2055-67. PubMed ID: 11360190
[TBL] [Abstract][Full Text] [Related]
34. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4.
Jinno S; Hung SC; Okayama H
Oncogene; 1999 Jan; 18(3):565-71. PubMed ID: 9989806
[TBL] [Abstract][Full Text] [Related]
35. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
Soni R; O'Reilly T; Furet P; Muller L; Stephan C; Zumstein-Mecker S; Fretz H; Fabbro D; Chaudhuri B
J Natl Cancer Inst; 2001 Mar; 93(6):436-46. PubMed ID: 11259469
[TBL] [Abstract][Full Text] [Related]
36. Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
Shafiq MI; Steinbrecher T; Schmid R
PLoS One; 2012; 7(8):e42612. PubMed ID: 22905154
[TBL] [Abstract][Full Text] [Related]
37. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo.
Lin J; Yan XJ; Chen HM
Cancer Chemother Pharmacol; 2007 Mar; 59(4):439-45. PubMed ID: 16816972
[TBL] [Abstract][Full Text] [Related]
38. Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4.
Chen S; Guan X; Wang LL; Li B; Sang XB; Liu Y; Zhao Y
Gene; 2017 Nov; 635():3-8. PubMed ID: 28888575
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia stimulates p16 expression and association with cdk4.
Zygmunt A; Tedesco VC; Udho E; Krucher NA
Exp Cell Res; 2002 Aug; 278(1):53-60. PubMed ID: 12126957
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Padmanabhan B; Adachi N; Kataoka K; Horikoshi M
J Biol Chem; 2004 Jan; 279(2):1546-52. PubMed ID: 14583612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
